Autologous Bone Marrow Aspirate Concentrate in Patients Undergoing Meniscectomy



Status:Not yet recruiting
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:November 2015
End Date:January 2020
Contact:Mukesh Ahuja, MBBS, MS
Email:mukesh.ahuja@rushortho.com
Phone:312-912-4699

Use our guide to learn which trials are right for you!

Prospective, Randomized, Double-blind Clinical Trial to Investigate the Efficacy of Autologous Bone Marrow Aspirate Concentrate Post-Meniscectomy

The proposed research study aims to evaluate the effects of autologous bone marrow aspirate
concentrate (BMAC) on the development and progression of osteoarthritis (OA) in patients
undergoing meniscectomy. This prospective, randomized, double-blind clinical trial will
compare patient-reported outcomes, specifically IKDC scores between patients who receive
BMAC post-meniscectomy and those who receive a saline control injection. The study will also
compare physical examination, MRI, radiographs, and synovial fluid analysis. Our hypothesis
is that those who receive the autologous BMAC injection after the procedure will have better
outcomes than those who do not.

Recent studies have demonstrated both the safety of BMAC intra-articular injection and
improvements in subjective, patient reported outcomes in patients with existing knee OA.
Unfortunately these studies were largely uncontrolled, underpowered, and/or retrospective in
nature. Additionally, a recent prospective, randomized clinical study of allograft
mesenchymal stem cells (MSCs) injected at a separate time point post surgical intervention
has highlighted the ability of MSCs to increase meniscal volume and improve knee pain
following injection.

This will be the first study to examine the effects of autograft BMAC intra-articular
injection in a single-stage procedure and in a prospective, randomized, double-blind
fashion. The results of this study, if the null hypothesis is rejected, will have
far-reaching implications for the standard of care in meniscal treatment and on OA
progression in the knee. Additionally, if the results of this study are favorable in
reduction of OA progression this study will change the surgical approach to all axial,
synovial joints including the shoulder, elbow, wrist, hip, and ankle.

Inclusion Criteria:

- Subject is greater than 18 years old

- Written informed consent is obtained

- Subject is determined to have a symptomatic meniscal tear requiring a meniscectomy

- Meniscal pathology is confirmed through MRI and arthroscopically

- Subject agrees to all follow-up evaluations

- Osteoarthritis Kellen-Lawrence grade 1-2 on flexion PA and extension AP views

Exclusion Criteria:

- Any subject lacking decisional capability

- Unwillingness to participate in the necessary follow-up

- Subject is pregnant or may become pregnant

- History of diabetes mellitus

- History of rheumatoid arthritis or other autoimmune disorder

- History of solid organ or hematologic transplantation

- Diagnosis of a non-basal cell malignancy within the preceding 5 years

- Infection requiring antibiotic treatment within the preceding 3 months

- Osteoarthritis Kellen-Lawrence grade 3 or 4 on flexion posteroanterior (PA) or
extension anteroposterior (AP) views

- Prior surgery on the index meniscus

- Concomitant surgery such as ligament surgery or cartilage repair or restoration

- Infection

- Prior cortisone/viscoscupplemtation/PRP injection within 6 weeks
We found this trial at
1
site
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Principal Investigator: Brian J Cole, MD, MBA
Phone: 312-563-2883
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials